Know what you’re in for before taking the risk. BbyY JOCELYN SOLIS-MOREIRA Semaglutides like Ozempic and Wegovy have weight loss benefits, but also some possibly harmful side effects. Jaap Arriens/NurPhoto via Getty ImagesSHARE You’ve probably heard a lot about Ozempic and Wegovy, the semaglutide wonder drugs for weight loss. Their newfound popularity with prescribers and online...
Mitchel L. Zoler, PhD October 26, 2023 TOPLINE: Among the 3188 people with type 2 diabetes who were adherent to their tirzepatide (Mounjaro, Lilly) regimen in four pivotal trials of the agent, a quarter achieved at least a 15% cut from their baseline body weight after 40–42 weeks of treatment, and researchers found seven baseline variables that...
by Nial Wheate and Jessica Pace, The Conversation ‘Budget Ozempic’ is really a laxative. Credit: ShutterstockSocial media is lighting up over what influencers are calling “budget Ozempic.” These are drugs normally used as laxatives and stool softeners, but people are taking them to lose weight. The demand is so high in the United States, there are...
UNIVERSITY OF CALIFORNIA, IRVINE The use of glucagon-like peptide-1 receptor agonists in weight-loss drugs like Ozempic and Wegovy to treat childhood obesity and type 2 diabetes may have unintended and adverse consequences for children’s health, according to a team of clinicians, exercise scientists, pharmaceutical scholars, ethicists, and behavioral experts. Their commentary appears as a perspective...
Miriam E. Tucker October 06, 2023 HAMBURG, Germany — The “twincretin” tirzepatide (Mounjaro) kept on producing “highly significant weight loss” when the drug was continued in a 1-year follow-up trial, and those who discontinued the drug regained some weight but not all. In Eli Lilly’s SURMOUNT-4 trial of 783 adults with obesity or overweight but not diabetes...
Peer-Reviewed Publication THE OBESITY SOCIETY ROCKVILLE, Md.—After adding follow-up years, increased sample sizes and examining multiple surgical procedures, new research shows bariatric surgery is associated with lower all-cancer and obesity-related cancer incidence among females. The research also found that cancer mortality was significantly lower among female surgical patients compared to non-surgical subjects, according to a...
Michael Orsini, Professor, Institute of Feminist and Gender Studies | School of Political Studies, L’Université d’Ottawa/University of Ottawa and Fady Shanouda, Assistant Professor, Critical Disability Studies, Carleton University. Following news of Ozempic’s ability to help its users lose weight, it did not take long for fat-haters to surface. (Justin Katigbak/Disabled And Here) The headlines squeal with...
Mitchel L. Zoler, PhD August 09, 2023 A novel triple agonist to receptors for three nutrient-stimulated hormones led to weight loss as high as 24% among people with overweight or obesity but who did not have type 2 diabetes when used at the highest tested dose for 48 weeks. The results are from a phase 2 study of retatrutide that was published in The New...
by Lori Solomon Among adults with overweight or obesity, the annual probability of weight loss of 5 percent or more was achieved by only one in 10, according to a study published online Aug. 7 in JAMA Network Open. Lyudmyla Kompaniyets, Ph.D., from the U.S. Centers for Disease Control and Prevention in Atlanta, and colleagues assessed...
Nathalie Raffier July 13, 2023 MARSEILLE, France — Setmelanotide can lead to significant weight loss that lasts for at least 3 years, according to results presented at the latest French Pediatric Society conference. The treatment is effective for adults and children alike. Setmelanotide is the culmination of two decades of research involving the identification of genes involved in early-onset obesity and...
